Reading PBH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PBH free→Reading PBH? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track PBH free→NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-06-15
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
Recent financial performance is strong, and management's recent track record has been steady, indicating a stable leadership environment. However, risk is elevated, and the sector backdrop presents a headwind, which could impact future performance. Peer multiples imply a price about 13% above where it trades (it looks cheap on this basis); the read is fair. The outlook hinges on guidance changes and sector trends, particularly the performance of major Healthcare bellwethers. This read is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 8 valuation methods, at three horizons. Current price $46.72. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $47 PBH trades at 11× p/e, below its 13× p/e peer median. Our $56 fair value sits above the price; high confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 16% below a flat-multiple fair value, below our forecast of about -4%. This describes what's priced in, not a forecast of the move.
Only weak execution quality, a turbulent sector regime (Heating) — not the full expensive x weak x turbulent stack.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 59% of the time over the next year (vs 52% for the rest of the cohort, n=2344).
Over the trailing year it converted 1.35x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 50% for the rest of the cohort, n=2269).
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, the US dollar, long-term interest rates, real (inflation-adjusted) rates, Fed net liquidity.
2 material management or governance events in the past 24 months, led by M&A activity. Historically, Health Care names rated stable grew net income 56% of the time over the next year (vs 52% for the rest of the cohort, n=618).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
EPS estimate $0.99 → $0.87 (-12.1% / 30d). 0 raised, 3 cut, 5 covering analysts.
0 upgrades, 0 downgrades / 30d. 71% of analysts rate Buy.
2 positive, 1 negative / 30d. See F4 management tile for the event list.
Divergence: fundamentals are strong but estimates are being cut. Worth reading the recent material events.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$118.
How much price usually moves either way.
On a bad day, this stock has moved -$289.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $4,633.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
No material changes since the prior snapshot.
as of 2026-06-15
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Why it matters: Fixing the last earnings miss is important for gaining back investor trust.
Confirms:Q1 earnings show a big improvement from the last quarter.
Disproves:Earnings miss expectations again or show no improvement from the last quarter.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for PBH yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Completion of Acquisition or Disposition of Assets. On June 12, 2026, the Borrower and Medtech Products Inc. (“MedTech”), a wholly-owned subsidiary of the Company, completed the previously announced acquisition of Breathe Right® and certain other brands (the “Breathe Right Business”) from Foundation Consumer Brands, LLC and certain of its affiliates, pursuant to an Asset Purchase Agreement, dated as of March 19, 2026 (the “Purchase Agreement”), for a purchase price of $1.045 billion in cash (…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
Looks cheaper than most peers in the same business.
Cheaper than its own typical valuation.
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
A side-by-side read on sector standing, valuation, and risk versus Pharmaceuticals.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
PBH Prestige Consumer Healthcare | Above typical Show detailsSector percentile: 81 of 100 | fair | elevated |
LLY Lilly (Eli) | Above typical Show detailsSector percentile: 88 of 100 | expensive | moderate |
JNJ Johnson & Johnson | Above typical Show detailsSector percentile: 74 of 100 | expensive | low |
MRK Merck & Co. | Typical Show detailsSector percentile: 67 of 100 | expensive | moderate |
PFE Pfizer | Typical Show detailsSector percentile: 61 of 100 | fair | low |
Not investment advice. As of 2026-06-15.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-15.
A guidance track record builds as the company issues and delivers on guidance.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
The company aims to grow by acquiring other businesses, as evidenced by recent acquisition announcements.
The company is focused on enhancing its operating income through various initiatives.
The company is working to address the recent earnings miss and improve financial performance.
Why it matters: This will show if the company can address the recent earnings miss. Investors will focus on any recovery in operating income.
Confirms one read:Earnings per share are better than expected. This shows signs of recovery.
Confirms the other:Earnings per share falls short of expectations, confirming ongoing issues.
Why it matters: This guidance shows how well Prestige is recovering from past supply problems. This is important for the Eye & Ear Care category.
Confirms one read:Organic revenue growth guidance for Q1 fiscal 2027 is above 3%.
Confirms the other:Organic revenue growth guidance for Q1 fiscal 2027 is below 1%.
Why it matters: If operating income keeps falling, it may show bigger profit problems. This can hurt investor trust.
Confirms:Operating income is below $75.5M in the next quarter.
Disproves:Operating income is above $75.5M in the next quarter.
Why it matters: This acquisition could boost growth and show management's commitment to expansion. Investors will look for signs of how this affects revenue.
Confirms:Look for positive revenue growth in the next quarter after the acquisition.
Disproves:Revenue growth fails to improve or declines in the next quarter after the acquisition.
Why it matters: Closing this deal will expand Prestige's portfolio in the therapeutic skin care market. It could enhance growth prospects and financial performance.
Confirms:The acquisition closes as planned in the second quarter of fiscal 2027.
Disproves:The deal may be delayed or not happen because of regulatory problems.
Why it matters: This purchase could help Prestige earn more money and grow in nasal strips.
Confirms:Breathe Right brings in over $200 million in revenue after the deal closes.
Disproves:Breathe Right does not meet revenue expectations after the acquisition.
Why it matters: Improvements in supply will support sales growth in the Eye & Ear Care category, which has been a challenge.
Confirms:Management says Clear Eyes can now make more products.
Disproves:Continued supply chain issues for Clear Eyes persist, impacting sales.
Entry into a Material Definitive Agreement. New Term Loan Facility On June 12, 2026 (the “Closing Date”), Prestige Consumer Healthcare Inc. (the “Company”) and its wholly-owned subsidiary, Prestige Brands, Inc. (the “Borrower”), entered into that certain Term Loan Credit Agreement (the “Term Loan Credit Agreement”) by and among the Company, the Borrower, certain other subsidiaries of the Company as guarantors, Citibank, N.A. as administrative agent, the lenders party thereto and Citibank, N.A…
Other Events. On June 15, 2026, the Company issued a press release announcing the Company’s entry into the Term Loan Credit Agreement, the ABL Amendment and the completion of the Transaction. A copy of the press release is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.
Creation of a Direct Financial Obligation or an Obligation under an Off Balance Sheet Arrangement of a Registrant. The information set forth in
Results of Operations and Financial Condition. On May 13, 2026, the Company announced financial results for the fiscal quarter and year ended March 31, 2026. A copy of the press release announcing the Company's earnings results for the fiscal quarter and year ended March 31, 2026 is attached to this Current Report on Form 8-K as Exhibit 99.1 and incorporated herein by reference.